Safety concerns: side effects and muscle loss

Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease. WHO recently published a guideline in JAMA on the use and indications of GLP-1 therapies for the treatment of #obesity in adults. Francesca Celletti, MD, PhD, and Ezekiel Emanuel, MD, PhD, join JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss. Related Content:

• World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults